Table 2:
Objective Tumor Response by Blinded Independent Central Review
| Extra-pancreatic NET Cohort | Pancreatic NET Cohort | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Tumor response | Cabozantinib | Placebo | p-value | Cabozantinib | Placebo | p-value |
| (N=134) | (N=69) | (N=64) | (N=31) | |||
| Objective response rate (95% CI) | 5% (2%−10%) | 0% (0%−5%) | 0.05 | 19% (10%−30%) | 0% (0%−11%) | 0.010 |
|
| ||||||
| Best overall response, n (%) | ||||||
|
| ||||||
| Partial Response | 7 (5%) | 0 | 12 (19%) | 0 | ||
|
| ||||||
| Stable Disease | 87 (65%) | 37 (54%) | 39 (61%) | 17 (55%) | ||
|
| ||||||
| Progressive Disease | 15 (11%) | 24 (35%) | 5 (8%) | 12 (39%) | ||
|
| ||||||
| Not Evaluable | 25 (19%) | 8 (12%) | 8 (13%) | 2 (6%) | ||
Abbreviations: CI: confidence interval
Objective response rate was defined as the percentage of patients who had a confirmed complete or partial response by blinded independent central review according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. All responses were partial responses. Chi-square tests were used to compare the response rates between the two groups.